Author Correction: Effects of switching from intravitreal injection of aflibercept to faricimab on ocular blood flow in patients with diabetic macular edema

Author Correction: Effects of switching from intravitreal injection of aflibercept to faricimab on ocular blood flow in patients with diabetic macular edema

Saved in:

Bibliographic Details
Main Authors:	Yoshinari Saima, Harumasa Yokota, Akifumi Kushiyama, Junya Hanaguri, Akira Ohno, Koyo Takase, Ruri Sugiyama, Kimimasa Muranaka, Satoru Yamagami, Taiji Nagaoka
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-06-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-025-03157-7
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effects of switching from intravitreal injection of aflibercept to faricimab on ocular blood flow in patients with diabetic macular edema
by: Yoshinari Saima, et al.
Published: (2024-06-01)

Two-year results of switching to intravitreal administration of faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration
by: Masaaki Saito, et al.
Published: (2025-08-01)

Short-term outcomes of faricimab and aflibercept 8 mg in diabetic macular edema
by: Carlo Maccauro, et al.
Published: (2025-07-01)

Safety Evaluation of Bilateral Same-Day Intravitreal Injection of Faricimab
by: Michael D. Karampelas, et al.
Published: (2025-06-01)

Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
by: Hang A, et al.
Published: (2024-12-01)

Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes
by: Alireza Lashay, et al.
Published: (2020-01-01)

Endophthalmitis in Retinopathy of Prematurity after Intravitreal Aflibercept Injection
by: Elcin Suren, et al.
Published: (2020-01-01)

Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials
by: Usha Chakravarthy, FRCOphth, PhD, et al.
Published: (2025-09-01)

Short-term real-world outcomes of diabetic macular edema treated with intravitreal faricimab.
by: Toshiaki Hirakata, et al.
Published: (2025-01-01)

Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys.
by: Alexander Tschulakow, et al.
Published: (2014-01-01)

Full-Thickness Macular Hole Formation After Intravitreal Faricimab Injection for Polypoidal Choroidal Vasculopathy
by: Tavonvunchai F, et al.
Published: (2025-06-01)

Single Intravitreal Aflibercept Injection for Unilateral Acute Nonarteritic Ischemic Optic Neuropathy
by: Ziya Ayhan, et al.
Published: (2015-01-01)

Efficacy and safety of intravitreal injection of aflibercept biosimilar for treating diabetic macular edema
by: Gaixia Zhai, et al.
Published: (2025-03-01)

Efficacy of intravitreal injection of Ziv-aflibercept before vitrectomy for proliferative diabetic retinopathy
by: Amin E. Nawar, et al.
Published: (2024-04-01)

Corrigendum: Efficacy and safety of intravitreal injection of aflibercept biosimilar for treating diabetic macular edema
by: Gaixia Zhai, et al.
Published: (2025-05-01)

Effect of Repeated Intravitreal Ranibizumab and Aflibercept Injections on the Cornea in Patients with Age-Related Macular Degeneration
by: Beata Urban, et al.
Published: (2020-01-01)

Unraveling the effects of serial intravitreal Aflibercept injections on the ocular surface of patients with glaucoma and retinal comorbidity
by: Luca Agnifili, et al.
Published: (2025-04-01)

Comparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
by: Jia-Kang Wang, et al.
Published: (2016-01-01)

The Effect Of Topical Anti-Glaucomatous Drops On Intraocular Pressure Changes In Patients Treated With Intravitreal Aflibercept
by: Mehmet Coşkun
Published: (2023-12-01)

Multicentre, randomised clinical trial comparing intravitreal aflibercept monotherapy versus aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) for the treatment of polypoidal choroidal vasculopathy
by: Tien Yin Wong, et al.
Published: (2021-07-01)

Baseline characteristics associated with the first year treatment interval of intravitreal faricimab in neovascular age-related macular degeneration (nAMD)
by: Sobha Sivaprasad, et al.
Published: (2024-12-01)

Intravitreal Ziv-Aflibercept in Treatment of Naïve Chronic Central Serous Chorioretinopathy Related Choroidal Neovascular Membrane
by: Nishant Radke, et al.
Published: (2017-01-01)

Comparison between intraocular pressure spikes following intravitreal aflibercept injections between phakic and pseudophakic eyes
by: Ahmed Chafrash, et al.
Published: (2024-12-01)

Plain language summary of publication of the 48-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema
by: David M. Brown, et al.
Published: (2025-07-01)

Real-world outcomes of a loading phase with intravitreal faricimab in refractory Neovascular Age-Related Macular Degeneration (nAMD) patients
by: Xu Yufeng, et al.
Published: (2025-07-01)

Managing Choroidal Neovascularization in Pseudoxanthoma Elasticum: Outcomes of Vitrectomy and Intravitreal Ranibizumab/Aflibercept Therapy—A Case Report
by: Kazuya Yamashita, et al.
Published: (2025-01-01)

Efficacy and safety of dexamethasone versus intravitreal aflibercept implants for macular edema: a systematic review and meta-analysis
by: Khaled Moghib, et al.
Published: (2025-04-01)

Intravitreal Aflibercept Injection and Photodynamic Treatment of a Patient with Unilateral Subretinal Neovascular Membrane Associated with Fundus Flavimaculatus
by: Ali Osman Saatci, et al.
Published: (2015-01-01)

A Case Report of Intravitreal Aflibercept for Iris Metastasis from Small Cell Lung Carcinoma with Neovascular Glaucoma
by: Hitoshi Goto, et al.
Published: (2025-02-01)

Early optical coherence tomography biomarkers for tailored frequency of intravitreal aflibercept in neovascular age-related macular degeneration
by: Gyeongsoo Lim, et al.
Published: (2025-03-01)

Efficacy of Faricimab in the Treatment of Diabetic Macular Edema and Faricimab-Related Changes in OCT and OCT Angiography
by: Dorota Śpiewak, et al.
Published: (2025-06-01)

Clinical characteristics and intravitreal aflibercept outcomes in patients aged 90 years and older with neovascular age-related macular degeneration
by: Feyzahan Uzun
Published: (2024-12-01)

Optic Coherence Tomography Angiography Findings of Bilateral Choroidal Neovascularization Associated with Optic Disc Drusen Treated with Intravitreal Aflibercept Injection
by: Melih Akıdan, et al.
Published: (2020-01-01)

Early real-world outcomes of intravitreal aflibercept 8 mg in treatment-Naïve neovascular AMD: AI-assisted fluid volume analysis
by: Jennifer Cattaneo, et al.
Published: (2025-04-01)

Comparative efficacy and safety of Faricimab with other intravitreal anti-vascular endothelial growth factor in the treatment of Neovascular age related macular degeneration- A Systematic review and meta-analysis
by: Renuga Devi Kaliaperumal, et al.
Published: (2025-05-01)

Comparative Efficacy of Intravitreal Aflibercept and Dexamethasone Implant in Treating Macular Edema Associated with Diabetic Retinopathy or Retinal Vein Occlusion: A Meta-Analysis and Systematic Review
by: Khaled Moghib, et al.
Published: (2025-01-01)

Human Factors Studies to Assess the Usability of the Faricimab Prefilled Syringe
by: Barakat MR, et al.
Published: (2025-02-01)

Effects of Intravitreal Aflibercept on the Systemic Insulin-like Growth Factor-I and Vascular Endothelial Growth Factor-A in Patients with Diabetic Retinopathy and Age-Related Macular Degeneration
by: Anna Lena Huber, et al.
Published: (2021-01-01)

12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept
by: Wajiha J Kheir, et al.
Published: (2025-01-01)

Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema
by: Wataru Kikushima, et al.
Published: (2025-02-01)